close
MENU
General Business
3 mins to read

Bitter-sweet year for AFT Pharmaceuticals due to Covid-19

Revenue up but profit growth modest as disruptions take their due.

Dita De Boni Mon, 24 May 2021

Difficulties and opportunities in the global health supply chain in the year of Covid have affected listed pharmaceuticals maker AFT.

In results out this morning for the financial year to the end of March 2021, the company reported record revenue of $113.1 million, up 7% on the year prior,

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Dita De Boni Mon, 24 May 2021
Contact the Writer: dita@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Bitter-sweet year for AFT Pharmaceuticals due to Covid-19
General Business,
87506
true